Skip to main content
Log in

Melphalan concentration dependent plasma protein binding in healthy humans and rats

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The binding of melphalan to plasma proteins from four healthy humans and from rats was measured by centrifugal ultrafiltration. Melphalan concentrations were determined by HPLC and by measuring 14C-melphalan activity. In whole blood, melphalan was distributed preferentially in plasma. However, a constant fraction, 37%, which was independent of the total melphalan concentration in whole blood, was present within the red blood cells. The binding of melphalan to plasma proteins from humans was less than that from rats. In both, however, the fraction bound was constant throughout the concentration range (0.1 to 9.0 µM) that is achieved during standard-dose melphalan therapy. Albumin was the primary binding protein. At concentrations equal to or in excess of 33 µM, which have been achieved during high-dose melphalan therapy, free plasma melphalan concentrations were no longer linearly related to total drug concentrations, and the plasma protein binding of melphalan in the human became concentration dependent. This occurred at concentrations of 70 µM in the rat. Scatchard analysis of the data indicated the presence of 2 groups of binding sites. Class I sites had 0.03 and 0.4 binding sites per albumin molecule in humans and rats, with respective association constants of 4.43 × 104M−1 and 1.92 × 104M−1. Class II sites had 5.18 and 2.60 binding sites per molecule, with repective association constants of 3.82 × 102M−1 and 2.01 × 102M−1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Abramson F, Jenkins J, Ostchega Y (1982) Effects of cancer and its treatment on plasma concentrations of α1-acid glycoprotein and propanolol binding. Clin Pharmacol Ther 32: 659–663

    Google Scholar 

  • Ahmed A, Hsu T, El-Azhary R, Moawad H, Costanzi J (1982) Macromolecular interactions of [14C-ring] melphalan in blood. Biochem Pharmacol 31: 1615–1619

    Google Scholar 

  • Alberts D, Chang S, Chen S, Moon T, Evans T, Furner R, Himmelstein J (1979) Kinetics of intravenous melphalan. Clin Pharmacol Ther 26: 73–80

    Google Scholar 

  • Ardiet C, Tranchand B, Biron P, Rebattu P, Philip T (1986) Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Cancer Chemother Pharmacol 16: 300–305

    Google Scholar 

  • Bosanquet A, Gilbey E (1982) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18: 355–362

    Google Scholar 

  • Casten D, Bodenhumer M, Burcham J (1943) A study of plasma protein variation in surgical procedure. Ann Surg 117: 52–73

    Google Scholar 

  • Chang S, Alberts D, Farquhar D, Melnick L, Walson P, Salmon S (1978) Hydrolysis and protein binding of melphalan. J Pharm Sci 67: 682–684

    Google Scholar 

  • Chang S, Alberts D, Melnick L, Walson P, Salmon S (1978) High-pressure liquid chromatographic analysis of melphalan plasma. J Pharm Sci 67: 679–682

    Google Scholar 

  • Chirigos M, Mead J (1964) Experiments on determination of melphalan by fluoresence. Interaction with protein and various solutions. Anal Biochem 7: 259–268

    Google Scholar 

  • Cornbleet M, Leonard R, Smyth J (1984) High-dose agent therapy: A review of clinical experiences. Cancer Drug Delivery 1: 227–238

    Google Scholar 

  • Cornbleet M, McElwain T, Kumar P, Filshie J, Selby P, Carter R, Hedley D, Clark M, Millar J (1983) Treatment of advanced melanoma with high-dose melphalan and autologous bone marrow transplatation. Br J Cancer 48: 329–334

    Google Scholar 

  • Doumas B, Watson W, Biggs H (1971) Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 31: 87

    Google Scholar 

  • Dunnett C (1964) New tables for multiple comparisons with a control. Biometrics 20: 482–491

    Google Scholar 

  • Ehrrson H, Lonroth U (1982) Degradation of melphalan in aqueous solutions; influence of human albumin binding. J Pharm Sci 71: 826–827

    Google Scholar 

  • Evans T, Chang S, Alberts D, Sipes I, Brendel K (1982) In vitro degradation of L-phenylalanine mustard. Cancer Chemother Pharmacol 8: 175–178

    Google Scholar 

  • Fisher B, Carbone P, Economons S (1975) L-Phenylalanine mustard in the management of primary breast cancer. A report of early findings. N Engl J Med 292: 117–122

    Google Scholar 

  • Flora K, Smith S, Cradock J (1979) Application of a simple high-performance liquid chromatographic method for the determination of melphalan in the presence of its hydrolysis products. J Chromatogr 177: 91–97

    Google Scholar 

  • Furner R, Brown R, Duncan G (1977) Pharmacokinetics of the absorption, distribution and elimination of melphalan (NSC-8806) in the dog. Cancer Treat Rep 61: 1637–1646

    Google Scholar 

  • George R, Doth J, Gordon D (1972) Multiple myeloma-intermittent combination chemotherapy compared to continous therapy. Cancer 29: 1665–1670

    Google Scholar 

  • Gornall A, Bradawill C, David M (1949) Determination of serum proteins by means of biuret reagent. J Biol Chem 177: 751

    Google Scholar 

  • Gouyette A, Hartmann O, Pico J (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16: 184–189

    Google Scholar 

  • Hersh M, Ludden T, Kuhn J. Knight W (1983) Pharmacokinetics of high dose melphalan. Invest New Drugs 1: 331–334

    Google Scholar 

  • Herzig R, Lazarus H, Forman W, Rekate H, Lowder J, Ingalls S (1981) Central nervous system penetration of high dose intravenous L-phenylalanine mustard. Proc Am Soc Clin Oncol 22: 531

    Google Scholar 

  • Jackson P, Tucker J, Woods H (1982) Altered plasma binding in cancer: Role of α1-acid glycoprotein and albumin. Clin Pharmacol Ther 32: 295–302

    Google Scholar 

  • Jusko W, Gretch M (1976) Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metabol Rev 5: 43–140

    Google Scholar 

  • Knott G (1979) M-Laba mathematical modeling tool. Comput Prog Biomed 10: 271–280

    Google Scholar 

  • Kyle R (1975) Multiple myeloma review of 869 cases. Mayo Clin Proc 50: 29–40

    Google Scholar 

  • Martin B (1965) Potential effect of the plasma proteins on drug distribution. Nature 207: 274–276

    Google Scholar 

  • Midler G, Alling E, Morton J (1950) Effect of neoplastic and allied diseases on concentration of plasma proteins. Cancer 3: 56–65

    Google Scholar 

  • Miller R (1966) Simultaneous statistical inference, McGraw-Hill, New York, pp 76–81

    Google Scholar 

  • Piver M, Barlow J, Lee F (1975) Sequential therapy for advanced ovarian adenocarcinoma: Operation, chemotherapy, second-look laparotomy and radiation therapy. Am J Obstet Gynecol 122: 355–357

    Google Scholar 

  • Rosin R, Westbury G (1980) Isolated limb perfusion for malignant melanoma. Practitioner 224: 1031–1036

    Google Scholar 

  • Ross W (1962) Alkylating agents. Biological alkylating agents. Butterworths, London, pp 3–31, 95–193

    Google Scholar 

  • Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–672

    Google Scholar 

  • Steele W, Lawrence J, Stuart J, McNeil C (1979) The protein binding of methotrexate by the serum of normal subjects. Eur J Clin Pharmacol 15: 363–366

    Google Scholar 

  • Steinfeld J (1960) I131 albumin degradation in patients with neoplastic diseases. Cancer 13: 974–984

    Google Scholar 

  • Sweeney D, Greig N, Rapoport S (1985) High-performance liquid chromatography analysis of melphalan in plasma, brain and peripheral tissue by o-phthaladehyde derivatization and fluorescence detection. J Chromatogr 339: 434–439

    Google Scholar 

  • Thorp J (1972) Inter and intra species differences in the binding of anionic compounds to albumin. Exerpta Medica Int Congr Ser 254: 98–109

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Greig, N.H., Sweeney, D.J. & Rapoport, S.I. Melphalan concentration dependent plasma protein binding in healthy humans and rats. Eur J Clin Pharmacol 32, 179–185 (1987). https://doi.org/10.1007/BF00542192

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00542192

Key words

Navigation